Matthew Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew Nguyen has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Ramy Hanna
Division of Nephrology, Department of Medicine, Hypertension and Kidney Transplantation, University of California, Irvine, Orange, USA
7 shared publications Dao Le
Division of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, University of California, Irvine, CA, USA
5 shared publications- Sohrab Kharabaf
Department of Medicine, Division of Nephrology, Hypertension, and Renal Transplant, University of California, Irvine, USA
2 shared publications Abanoub Massoud
AM consulting company
1 shared publication- Aldo Arce
Division of Nephrology, Hypertension, and Transplant Nephrology, University of California, Irvine, CA, USA
1 shared publication Anthony Sisk
Division of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA
1 shared publication
Latest Publications
- 5 August 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (10) , 1477-1479
How I Treat
- 5 August 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (10) , 1477-1479
How I Treat
- Open Access
- 18 July 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Controlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report
Focal segmental glomerulosclerosis is a histopathological condition characterized by podocyte injury, which manifests as persistent proteinuria and progressive decline in renal function. It is classified into primary and secondary forms, with secondary focal segmental glomerulosclerosis often resulting from factors such as obesity, hypertension, or genetic mutations. The management of secondary focal segmental glomerulosclerosis remains challenging due to the lack of standardized therapeutic guidelines. This case report describes a 21-year-old male diagnosed with biopsy-proven secondary focal segmental glomerulosclerosis, likely due to obesity-related hyperfiltration, who exhibited significant improvement in proteinuria following cyclosporine therapy. Despite initial treatment with renin–angiotensin system inhibitors and prednisone, the patient continued to have persistent proteinuria. Low-dose cyclosporine therapy was introduced, leading to a marked reduction in proteinuria without deterioration in renal function. This case highlights the potential role of cyclosporine in the management of secondary focal segmental glomerulosclerosis, particularly in cases with suspected genetic predisposition. Further research is needed to determine the long-term efficacy and safety of cyclosporine in secondary focal segmental glomerulosclerosis management.
- 18 July 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Open AccessControlling proteinuria in secondary focal segmental glomerulosclerosis with cyclosporine: A case report
Focal segmental glomerulosclerosis is a histopathological condition characterized by podocyte injury, which manifests as persistent proteinuria and progressive decline in renal function. It is classified into primary and secondary forms, with secondary focal segmental glomerulosclerosis often resulting from factors such as obesity, hypertension, or genetic mutations. The management of secondary focal segmental glomerulosclerosis remains challenging due to the lack of standardized therapeutic guidelines. This case report describes a 21-year-old male diagnosed with biopsy-proven secondary focal segmental glomerulosclerosis, likely due to obesity-related hyperfiltration, who exhibited significant improvement in proteinuria following cyclosporine therapy. Despite initial treatment with renin–angiotensin system inhibitors and prednisone, the patient continued to have persistent proteinuria. Low-dose cyclosporine therapy was introduced, leading to a marked reduction in proteinuria without deterioration in renal function. This case highlights the potential role of cyclosporine in the management of secondary focal segmental glomerulosclerosis, particularly in cases with suspected genetic predisposition. Further research is needed to determine the long-term efficacy and safety of cyclosporine in secondary focal segmental glomerulosclerosis management.
- Open Access
- 27 June 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (8) , sfaf206
Intravitreal vascular endothelial growth factor inhibitor systemic and renal toxicity registry
Background: Intravitreal vascular endothelial growth factor inhibitors (IVEGFi) are used in the treatment of diabetic retinopathy, age-related macular degeneration (AMD) and central retinal vein obstruction. As we have previously reported, there are an increasing number of cases documenting IVEGFi with renal injury and increased concentrations in the serum. To assess this claim, we have developed a novel reporting system through an electronic registry for cases of suspected VEGFi injury. Methods: A website with multiple data protection sets was created to educate, promote awareness and capture patient cases of suspected IVEGFi toxicity. The website displays the molecular biology of VEGF signaling, the process of absorption into the bloodstream, and study reports showing risks on case, cohort and epidemiologic levels. A Health Insurance Portability and Accountability Act (HIPAA)-compliant patient intake form was designed to collect renal, cardiovascular, cerebrovascular, renal biopsy and function data along with drug type, indication and frequency of administration. Results: In our updated cohort we added 16 total cases from the literature showing signs of renal injury from the patient population receiving VEGFi. In current literature, 46 cases of VEGFi-related renal injury have been documented. To them, we add our 16 cases for a total of 62 cases. Conclusion: The current database for VEGFi-related nephrotoxicity constitutes the largest case series presented for this condition. This study opens the door for future studies to evaluate what subgroups experience acute kidney injury, proteinuria and hypertension exacerbations. Additionally, we may expand on our database to include timeline markers for symptomatic-correlative VEGFi usage and, in time, predictive measures on a larger scale to correlate comorbidity/drug use with drug effect and mechanism of action.
- 27 June 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (8) , sfaf206
Open AccessIntravitreal vascular endothelial growth factor inhibitor systemic and renal toxicity registry
Background: Intravitreal vascular endothelial growth factor inhibitors (IVEGFi) are used in the treatment of diabetic retinopathy, age-related macular degeneration (AMD) and central retinal vein obstruction. As we have previously reported, there are an increasing number of cases documenting IVEGFi with renal injury and increased concentrations in the serum. To assess this claim, we have developed a novel reporting system through an electronic registry for cases of suspected VEGFi injury. Methods: A website with multiple data protection sets was created to educate, promote awareness and capture patient cases of suspected IVEGFi toxicity. The website displays the molecular biology of VEGF signaling, the process of absorption into the bloodstream, and study reports showing risks on case, cohort and epidemiologic levels. A Health Insurance Portability and Accountability Act (HIPAA)-compliant patient intake form was designed to collect renal, cardiovascular, cerebrovascular, renal biopsy and function data along with drug type, indication and frequency of administration. Results: In our updated cohort we added 16 total cases from the literature showing signs of renal injury from the patient population receiving VEGFi. In current literature, 46 cases of VEGFi-related renal injury have been documented. To them, we add our 16 cases for a total of 62 cases. Conclusion: The current database for VEGFi-related nephrotoxicity constitutes the largest case series presented for this condition. This study opens the door for future studies to evaluate what subgroups experience acute kidney injury, proteinuria and hypertension exacerbations. Additionally, we may expand on our database to include timeline markers for symptomatic-correlative VEGFi usage and, in time, predictive measures on a larger scale to correlate comorbidity/drug use with drug effect and mechanism of action.
- Open Access
- 20 June 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Unique genetic presentation of Gitelman syndrome in a Hispanic patient: Case report
Gitelman’s syndrome, also known as, familial hypokalemia–hypomagnesemia, is a renal tubulopathy responsible for salt wasting resulting in, hypomagnesemia, hypocalciuria, and secondary activation of the renin–angiotensin–aldosterone system, responsible for the hypokalemia and metabolic alkalosis. Gitelman’s syndrome is due to a rare, autosomal recessive gene mutation due to deletions, missense, nonsense, frame-shift, and splice-site mutation in the solute carrier family 12, member 3 gene. Solute carrier family 12, member 3, encodes a thiazide-sensitive sodium–chloride cotransporter in the apical membrane of cells within the distal convoluted tubule, leading to the development of Gitelman’s syndrome. An 18-year-old male patient with a past medical history of chronic hypokalemia, hypomagnesemia, and constipation presented to the clinic as a continuation of care from his pediatric nephrologist for previously diagnosed Gitelman’s syndrome in his childhood. Regarding his history of Gitelman’s syndrome leading up to his diagnosis, at the age of 3, the patient was found to be hypokalemic on routine testing with no identifiable cause. The patient underwent genetic testing, where the test result demonstrated a positive solute carrier family 12, member 3 gene mutation, concurrent with Gitelman’s syndrome. On genetic testing, heterozygous variants were also detected c. 179C>T, which is a known disease-causing mutation. Currently, the patient is being monitored due to persistent hydronephrosis of the bilateral kidneys. The patient has constantly dealt with hydronephrosis; however, kidney function has been preserved. The c.179C>T (Thr60Met) variant has been used to identify individuals with Gitelman’s syndrome due to this mutation being the most common, thought to be found in 1–10/40,000 individuals, with higher prevalence within Asian demographics. Literature shows a greater association of Japanese and Chinese descent when compared to other demographic groups. This finding in an individual of Hispanic origin should increase suspicion that this finding can be found in individuals, not of Asian descent.
- 20 June 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Open AccessUnique genetic presentation of Gitelman syndrome in a Hispanic patient: Case report
Gitelman’s syndrome, also known as, familial hypokalemia–hypomagnesemia, is a renal tubulopathy responsible for salt wasting resulting in, hypomagnesemia, hypocalciuria, and secondary activation of the renin–angiotensin–aldosterone system, responsible for the hypokalemia and metabolic alkalosis. Gitelman’s syndrome is due to a rare, autosomal recessive gene mutation due to deletions, missense, nonsense, frame-shift, and splice-site mutation in the solute carrier family 12, member 3 gene. Solute carrier family 12, member 3, encodes a thiazide-sensitive sodium–chloride cotransporter in the apical membrane of cells within the distal convoluted tubule, leading to the development of Gitelman’s syndrome. An 18-year-old male patient with a past medical history of chronic hypokalemia, hypomagnesemia, and constipation presented to the clinic as a continuation of care from his pediatric nephrologist for previously diagnosed Gitelman’s syndrome in his childhood. Regarding his history of Gitelman’s syndrome leading up to his diagnosis, at the age of 3, the patient was found to be hypokalemic on routine testing with no identifiable cause. The patient underwent genetic testing, where the test result demonstrated a positive solute carrier family 12, member 3 gene mutation, concurrent with Gitelman’s syndrome. On genetic testing, heterozygous variants were also detected c. 179C>T, which is a known disease-causing mutation. Currently, the patient is being monitored due to persistent hydronephrosis of the bilateral kidneys. The patient has constantly dealt with hydronephrosis; however, kidney function has been preserved. The c.179C>T (Thr60Met) variant has been used to identify individuals with Gitelman’s syndrome due to this mutation being the most common, thought to be found in 1–10/40,000 individuals, with higher prevalence within Asian demographics. Literature shows a greater association of Japanese and Chinese descent when compared to other demographic groups. This finding in an individual of Hispanic origin should increase suspicion that this finding can be found in individuals, not of Asian descent.
- Open Access
- 13 May 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Rituximab treatment in non-lupus full-house nephropathy: A case report
Non-lupus full-house nephropathy describes a pattern of “full-house” immunofluorescence on renal biopsy in the absence of clinical or serologic markers for systemic lupus erythematosus. It is a rare disease with a broad range of etiologies, including idiopathic, secondary, or a prodrome of systemic lupus erythematosus. Current treatment options are lacking, with mixed results in the literature for varied immunosuppressive regimens. Rituximab, a selective anti-CD20 B-cell monoclonal antibody, has shown success in immune-complex mediated glomerular diseases but has not been commonly used or studied in non-lupus full-house nephropathy. Here, we present a case of non-lupus full-house nephropathy that was refractory to first-line immunosuppressants, in which two rounds of rituximab treatment achieved a positive response. This case emphasizes the need for systemic analysis of rituximab use in non-lupus full-house nephropathy, particularly given its mixed etiologies and presentations.
- 13 May 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Open AccessRituximab treatment in non-lupus full-house nephropathy: A case report
Non-lupus full-house nephropathy describes a pattern of “full-house” immunofluorescence on renal biopsy in the absence of clinical or serologic markers for systemic lupus erythematosus. It is a rare disease with a broad range of etiologies, including idiopathic, secondary, or a prodrome of systemic lupus erythematosus. Current treatment options are lacking, with mixed results in the literature for varied immunosuppressive regimens. Rituximab, a selective anti-CD20 B-cell monoclonal antibody, has shown success in immune-complex mediated glomerular diseases but has not been commonly used or studied in non-lupus full-house nephropathy. Here, we present a case of non-lupus full-house nephropathy that was refractory to first-line immunosuppressants, in which two rounds of rituximab treatment achieved a positive response. This case emphasizes the need for systemic analysis of rituximab use in non-lupus full-house nephropathy, particularly given its mixed etiologies and presentations.
- Open Access
- 1 January 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Dasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report
Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase inhibitors. Dasatinib, a tyrosine kinase inhibitor used in managing chronic myeloid leukemia, has been linked to thrombotic microangiopathy. This report describes a 66-year-old female with chronic myeloid leukemia treated with dasatinib who developed renal-limited thrombotic microangiopathy. Progressive renal dysfunction found in the context of chronic kidney disease prompted extensive lab evaluation and evaluation, with a renal biopsy confirming thrombotic microangiopathy attributed to dasatinib-induced nephrotoxicity. Discontinuation of dasatinib led to a slight improvement in renal function; however, progressive decline necessitated dialysis. This case underscores the diagnostic and therapeutic challenges of dasatinib-induced thrombotic microangiopathy, emphasizing renal biopsy in diagnosis and monitoring. Individualized treatment strategies and further research should be conducted to optimize future outcomes.
- 1 January 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Open AccessDasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report
Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase inhibitors. Dasatinib, a tyrosine kinase inhibitor used in managing chronic myeloid leukemia, has been linked to thrombotic microangiopathy. This report describes a 66-year-old female with chronic myeloid leukemia treated with dasatinib who developed renal-limited thrombotic microangiopathy. Progressive renal dysfunction found in the context of chronic kidney disease prompted extensive lab evaluation and evaluation, with a renal biopsy confirming thrombotic microangiopathy attributed to dasatinib-induced nephrotoxicity. Discontinuation of dasatinib led to a slight improvement in renal function; however, progressive decline necessitated dialysis. This case underscores the diagnostic and therapeutic challenges of dasatinib-induced thrombotic microangiopathy, emphasizing renal biopsy in diagnosis and monitoring. Individualized treatment strategies and further research should be conducted to optimize future outcomes.
- Open Access
- 30 September 2024
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 43 (5) , 575-585
Personalized nutritional management in the transition from non-dialysis dependent chronic kidney disease to dialysis
Dialysis has been the dominant treatment regimen in end-stage kidney disease as a means to remove uremic waste products and to maintain electrolyte, acid base, and fluid balance. However, given that dialysis may not always provide a survival benefit nor improved quality of life in certain subpopulations, there is growing recognition of the need for conservative and preservative management as an alternative treatment strategy for advanced chronic kidney disease (CKD). Personalized nutritional management tailored to patient’s sociodemographics, social needs, psychological status, health literacy level, and preferences is a key component of conservative and preservative care, as well as in the management of patients transitioning from non-dialysis dependent CKD to dialysis. In this review, we discuss the nutritional and metabolic alterations that ensue in CKD; the rationale for low-protein diets in the conservative and preservative management of advanced CKD; the role of plant-based diets in kidney health; emerging data on dietary potassium and sodium intake on CKD outcomes; and the practical implementation of dietary interventions in advanced kidney disease.
- 30 September 2024
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 43 (5) , 575-585
Open AccessPersonalized nutritional management in the transition from non-dialysis dependent chronic kidney disease to dialysis
Dialysis has been the dominant treatment regimen in end-stage kidney disease as a means to remove uremic waste products and to maintain electrolyte, acid base, and fluid balance. However, given that dialysis may not always provide a survival benefit nor improved quality of life in certain subpopulations, there is growing recognition of the need for conservative and preservative management as an alternative treatment strategy for advanced chronic kidney disease (CKD). Personalized nutritional management tailored to patient’s sociodemographics, social needs, psychological status, health literacy level, and preferences is a key component of conservative and preservative care, as well as in the management of patients transitioning from non-dialysis dependent CKD to dialysis. In this review, we discuss the nutritional and metabolic alterations that ensue in CKD; the rationale for low-protein diets in the conservative and preservative management of advanced CKD; the role of plant-based diets in kidney health; emerging data on dietary potassium and sodium intake on CKD outcomes; and the practical implementation of dietary interventions in advanced kidney disease.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 12
May-Hegglin anomaly associated nephropathy: Case series
May-Hegglin anomaly (MHA) is a rare autosomal dominant disease associated with a mutation in the MYH-9 gene. It is characterized by macrothrombocytopenia and neutrophils with abnormal cytoplasmic inclusions. Clinical features of this disease include hearing loss, early cataracts, and renal failure. We present two interesting cases of renal injury attributed to MHA. The first is a 52-year-old Hispanic female with MHA-associated nephropathy and thrombocytopenia complicated by Stage 3 chronic kidney disease (CKD) and hypothyroidism. She was found to have a pathogenic MYH-9 heterozygous mutation with associated clinical characteristics. Due to her thrombocytopenia from MHA, patient is not a candidate for kidney biopsy. She has been treated with SGLT-2 inhibitors, Angiotensin Receptor Blockers (ARBs) for managing her Stage 3b CKD and Synthroid® for hypothyroidism. Despite these treatments, she continues to have low platelet counts, proteinuria, and progressive CKD. Our second case highlights a 39-year-old white female with MHA associated with focal segmental glomerulosclerosis diagnosed at the age of 15 on renal biopsy. She also has thrombocytopenia and mixed connective tissue disease with rheumatoid arthritis and systemic lupus erythematosus clinical characteristics. She is currently on a regimen of methotrexate, Xeljanz, and IVIG for her rheumatological diseases. Her kidney function has remained stable on Angiotensin Converting Enzyme Inhibitors (ACEi) with hydrochlorothiazide and as needed loop diuretics for edema. These cases illustrate the challenges of diagnosing and managing renal complications associated with MHA due to the MYH-9 gene mutation. Chronic thrombocytopenia in both patients restricts the use of invasive diagnostic procedures, such as biopsies, which are critical for confirming the relationship between nephropathy and MHA, and for guiding further treatment. As such, these cases stress the importance of genetic testing as a key tool in diagnosis and emphasize the difficulties in managing patients with suspected MHA-associated nephropathy and thrombocytopenia.
- 1 January 2024
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 12
Open AccessMay-Hegglin anomaly associated nephropathy: Case series
May-Hegglin anomaly (MHA) is a rare autosomal dominant disease associated with a mutation in the MYH-9 gene. It is characterized by macrothrombocytopenia and neutrophils with abnormal cytoplasmic inclusions. Clinical features of this disease include hearing loss, early cataracts, and renal failure. We present two interesting cases of renal injury attributed to MHA. The first is a 52-year-old Hispanic female with MHA-associated nephropathy and thrombocytopenia complicated by Stage 3 chronic kidney disease (CKD) and hypothyroidism. She was found to have a pathogenic MYH-9 heterozygous mutation with associated clinical characteristics. Due to her thrombocytopenia from MHA, patient is not a candidate for kidney biopsy. She has been treated with SGLT-2 inhibitors, Angiotensin Receptor Blockers (ARBs) for managing her Stage 3b CKD and Synthroid® for hypothyroidism. Despite these treatments, she continues to have low platelet counts, proteinuria, and progressive CKD. Our second case highlights a 39-year-old white female with MHA associated with focal segmental glomerulosclerosis diagnosed at the age of 15 on renal biopsy. She also has thrombocytopenia and mixed connective tissue disease with rheumatoid arthritis and systemic lupus erythematosus clinical characteristics. She is currently on a regimen of methotrexate, Xeljanz, and IVIG for her rheumatological diseases. Her kidney function has remained stable on Angiotensin Converting Enzyme Inhibitors (ACEi) with hydrochlorothiazide and as needed loop diuretics for edema. These cases illustrate the challenges of diagnosing and managing renal complications associated with MHA due to the MYH-9 gene mutation. Chronic thrombocytopenia in both patients restricts the use of invasive diagnostic procedures, such as biopsies, which are critical for confirming the relationship between nephropathy and MHA, and for guiding further treatment. As such, these cases stress the importance of genetic testing as a key tool in diagnosis and emphasize the difficulties in managing patients with suspected MHA-associated nephropathy and thrombocytopenia.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 11
Tolvaptan-induced isolated elevation of bilirubin in a patient with Gilbert syndrome
Tolvaptan is the current standard of treatment for autosomal dominant polycystic kidney disease. It operates by acting on V2 receptors and blocks vasopressin interactions, causing a reduction in the rate of renal cyst growth and preserving kidney function. The current known risks of tolvaptan involve a serious liver injury characterized by an elevation in total bilirubin and alanine transaminase and aspartate transaminase levels. In this report, we document a unique liver injury characterized by an elevated bilirubin with normal alanine transaminase and aspartate transaminase levels in a patient who is homozygous for the UGT1A1 consistent with Gilbert syndrome.
- 1 January 2023
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 11
Open AccessTolvaptan-induced isolated elevation of bilirubin in a patient with Gilbert syndrome
Tolvaptan is the current standard of treatment for autosomal dominant polycystic kidney disease. It operates by acting on V2 receptors and blocks vasopressin interactions, causing a reduction in the rate of renal cyst growth and preserving kidney function. The current known risks of tolvaptan involve a serious liver injury characterized by an elevation in total bilirubin and alanine transaminase and aspartate transaminase levels. In this report, we document a unique liver injury characterized by an elevated bilirubin with normal alanine transaminase and aspartate transaminase levels in a patient who is homozygous for the UGT1A1 consistent with Gilbert syndrome.